The Motley Fool Previous Page

Can Eli Lilly Save This Drug?

Brian Orelli
July 13, 2012

A replacement for Zyprexa, pomaglumetad methionil is not. Or maybe it is. Feeling a little schizophrenic? So, too, ┬áit seems is Eli Lilly (NYSE: LLY  ) .

The pharma announced that two different doses of the drug failed to show an effect in patients with schizophrenia compared to placebo. Eli Lilly even subdivided the treatment groups in the phase 3 trial based on predefined genetic differences of the patie